Research body opens market engagement on genomic sequencing services
A biomedical research institute is preparing to outsource whole exome and RNA sequencing for 800 patient samples in a disease-focused research study.
A biomedical research institute is preparing to outsource whole exome and RNA sequencing for 800 patient samples in a disease-focused research study.
Follow Tenderlake on LinkedIn for concise insights on public-sector tenders and emerging procurement signals.
In March 2026, the Director Científico del Instituto de Investigación Biomédica de Salamanca (IBSAL) published a Prior Information Notice for a planned sequencing service for patient samples. The institute intends to hire a provider to prepare and carry out genetic analysis on 800 patient samples, split between 500 whole exome sequencing (WES) and 300 RNA sequencing (RNAseq) runs, in support of a research initiative on myelodysplastic syndromes in Spain.
The notice, dated 30th March 2026, sets out a clear focus on patient-level genomic data. Rather than investing in new instruments, IBSAL plans to contract in both sample preparation and genetic analysis as a single service. The provider will handle the full workflow for 800 patient samples, a scale that points to a sizeable research cohort.
The split between 500 WES and 300 RNAseq samples shows that the project is not limited to a single assay type. By combining DNA-focused exome sequencing with RNA-based analysis, the study team can draw on more than one layer of genomic information from each patient group. For suppliers, that mix brings technical and logistical implications, from how they schedule different runs to how they manage quality control across multiple methodologies.
The project underlines how genomic methods are moving to the centre of disease-focused research programmes. Because the samples are from patients, issues such as data quality, traceability and turnaround times will matter to downstream collaborators, even though the immediate aim is research rather than routine diagnostics. The Prior Information Notice marks an early step in the procurement process for this service, giving sequencing providers a view of expected scope and volumes ahead of any full tender.
IBSAL is far from alone in turning to external partners for advanced sequencing. In November 2025, Rīgas Stradiņa universitāte launched a contract notice for NGS outsourcing services that range from prepared library sequencing and long-read technologies to targeted amplicon work and methylation microarray analysis. That notice framed sequencing squarely as an external service, giving researchers access to a wide menu of options without owning every platform themselves.
Several biomedical research bodies have taken a similar path. In December 2025, Fundación Instituto de Investigación Sanitaria Illes Balears issued a tender for genomic sequencing services covering whole genome sequencing (WGS) and RNAseq across a range of biomedical projects. That same month, Université catholique de Louvain set up a framework agreement for high-throughput sequencing services using both Illumina and PacBio platforms, including methylation profile decoding. In February 2026, Asociación Centro de Investigación Cooperativa en Biociencias-CIC bioGUNE followed with its own call for a mass sequencing service.
Taken together, these procurements show research organisations buying access to capacity and expertise rather than only instruments and reagents. IBSAL’s plan to outsource preparation and analysis of 800 samples for a single disease-focused project fits this pattern. For sequencing companies and academic core facilities, that may mean growing opportunities to compete for project-based work alongside longer-term framework agreements.
At the same time, many public buyers continue to invest heavily in their own sequencing infrastructure. In November 2025, the Rectorado de la Universidad de Málaga sought the supply and installation of a next-generation sequencing platform and automated sample preparation equipment to expand its Genomics and Next-Generation Sequencing Unit. In December 2025, CHU de Lille went further, procuring a complete genomic profiling solution for solid tumours that integrates next-generation sequencing technologies and computational analysis tools.
These hardware-led projects illustrate how hospitals and universities are building permanent capacity for genomics. Rather than choosing between in-house equipment and external services, many systems appear to be moving towards hybrid models. High-throughput platforms can handle core diagnostic and research workloads, while specialised or peak-demand projects, such as IBSAL’s 800-sample myelodysplastic syndrome study, are contracted out to service providers.
As sequencing volumes rise, procurement is also shifting towards software and cloud-based analysis. In January 2026, Univerzitetni klinični center Maribor opened a contract notice to acquire software for interpreting exome and genome sequencing data. The specification focuses on turning WES and WGS output into interpretable findings for clinicians and researchers.
On 30th March 2026, Leids Universitair Medisch Centrum published a notice for an NGS analysis platform for its Clinical Genetics department, specifying tools to annotate, classify, filter, prioritise and report genetic variants from whole genome sequencing data. And in December 2025, Meditsinski universitet-Varna 'Prof. d-r Paraskev Iv. Stoyanov' sought a 12‑month subscription to a cloud platform for managing sequencing processes and bioinformatics analysis, together with software for variant interpretation and sequencing data reporting.
IBSAL’s planned procurement already combines wet-lab work with 'genetic analysis' as an explicit part of the service description. That wording implies that the chosen provider will not stop at raw sequencing, but will also contribute to downstream analysis. When the detailed specification appears, it will be important for the institute to spell out what analytical outputs it expects, and how they should align with existing research data standards.
For potential suppliers, the IBSAL project brings together several trends. The volume of 800 patient samples, with a mix of WES and RNAseq, will favour organisations that can manage high-throughput workflows while maintaining clear communication with disease-focused research teams. The fact that the work is framed as a discrete project, rather than a broad multi-disease framework, may also appeal to specialised service providers that prefer tightly scoped engagements.
From a public-sector perspective, the notice shows how research institutes are using procurement to balance flexibility, cost and access to expertise. Some are building multi-year frameworks or investing in permanent platforms; others, like IBSAL in this case, are using project-based contracts to secure advanced technologies for a defined study. How that mix evolves will shape the competitive landscape for sequencing companies, informatics vendors and academic facilities across Europe.
The Prior Information Notice does not yet set out detailed technical or contractual requirements. If a full tender follows, observers will be able to see how IBSAL defines quality thresholds for WES and RNAseq data, how it structures turnaround expectations for the 800 samples, and what level of bioinformatic processing it expects suppliers to provide. Those choices will indicate whether future research projects in Spain are more likely to rely on outsourcing for complex sequencing, or whether this contract becomes a bridge towards larger, shared genomic infrastructures.
Follow Tenderlake on LinkedIn for concise insights on public-sector tenders and emerging procurement signals.